(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of 101.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Praxis Precision Medicines's revenue in 2025 is $7,765,000.On average, 1 Wall Street analysts forecast PRAX's revenue for 2025 to be $69,808,856, with the lowest PRAX revenue forecast at $69,808,856, and the highest PRAX revenue forecast at $69,808,856. On average, 3 Wall Street analysts forecast PRAX's revenue for 2026 to be $1,144,785,257, with the lowest PRAX revenue forecast at $122,170,759, and the highest PRAX revenue forecast at $3,156,867,150.
In 2027, PRAX is forecast to generate $1,253,570,899 in revenue, with the lowest revenue forecast at $270,227,828 and the highest revenue forecast at $3,732,890,176.